NJ-LARSEN-&-TOUBRO-INFOT
2.11.2022 20:46:36 CET | Business Wire | Press release
Fosfor, the Data Products Unit of Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), today announced that it has been approved as a Snowflake Ready Technology Validation Partner. Achieving this validation confirms Fosfor’s DataOps product, Spectra, and Decision Intelligence product, Lumin, adhere to Snowflake’s best practices around performance, reliability, and security.
Under the Snowflake Ready Technology Validation program, Snowflake audits and validates a company’s native integration with Snowflake based on functional and performance best practices. The audit requires a native connector that has been available for at least six months, as well as a set of joint customers and case studies. With this validation, Fosfor joins a list of prominent product companies that have been approved under this program.
“Efficient access to quality data helps organizations quickly inform strategies and decisions – it is a must-have for our customers," says Tarik Dwiek, Head of Technology Alliances at Snowflake. “Fosfor’s take on monetizing data at speed and scale for enterprises complements Snowflake's commitment to capitalizing on the infinite potential of the Data Cloud and creates a winning proposition for our customers.”
Along with LTI recently being awarded Elite tier partner status and receiving the Delivery Partner of the Year award at the 2022 Snowflake Summit, the Technology Ready designation further reinforces the long-standing partnership between the companies. A growing number of Fosfor customers are realizing the synergistic value created by combining Fosfor’s data and AI capabilities with Snowflake’s Data Cloud.
“The Snowflake-Fosfor partnership is a natural fit in exploding value from Data & AI for enterprises globally and is creating immense value for our joint customers with Fosfor products’ seamless native connectivity to Snowflake. Fosfor products like Spectra are solving major DataOps challenges for enterprises, while Lumin converts data into decision insights with ease for business users,” said Satyakam Mohanty, Chief Product Officer, Fosfor. "We are delighted to be in lockstep with Snowflake to strengthen our valued partnership and in our aligned vision to create limitless business impact for enterprises.”
Snowflake has been a key partner of LTI since 2018, and of the Fosfor product suite since its launch in December of 2021. Click here to learn more about the powerful combination of Fosfor and Snowflake.
About Fosfor
The Fosfor Product Suite is the only end-to-end suite for optimizing all aspects of the data-to-decisions lifecycle. Fosfor helps you make better decisions, ensuring you have the right data in more hands in the fastest time possible. The Fosfor Product Suite comprises of Spectra, a comprehensive DataOps platform; Aspect, a no-code unstructured data processing platform; Optic, a data fabric to facilitate data discovery-to-consumption journeys; Refract, a data science and MLOps platform; and Lumin, a decision intelligence platform. Collectively, the Fosfor suite helps businesses discover the hidden value in their data. The Fosfor Data Products Unit is part of LTI, a global technology consulting and digital solutions company with hundreds of clients and operations in 33 countries. For more information, visit www.fosfor.com.
About LTI:
LTI (NSE: LTI) is a global technology consulting and digital solutions company helping more than 500 clients succeed in a converging world. With operations in 33 countries, we go the extra mile to assist our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 50,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Learn more at http://www.lntinfotech.com or follow us at @LTI_Global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005946/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom